Media headlines about Macrocure (NASDAQ:MCUR) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Macrocure earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9896762086494 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

ILLEGAL ACTIVITY WARNING: “Macrocure (MCUR) Given Daily News Impact Score of 0.09” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/16/macrocure-mcur-given-daily-news-impact-score-of-0-09.html.

Macrocure Company Profile

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

Insider Buying and Selling by Quarter for Macrocure (NASDAQ:MCUR)

Receive News & Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related companies with MarketBeat.com's FREE daily email newsletter.